← Back to Search

Behavioural Intervention

Accelerated TMS for Depression and OCD

N/A
Recruiting
Led By Conor Liston, MD, PhD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of major depressive disorder OR obsessive-compulsive disorder (DSM-V criteria)
Failure to respond in the current episode to at least one antidepressant or other pharmacotherapy at an adequate dose and duration as measured by a modified antidepressant treatment history
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
No Placebo-Only Group

Study Summary

This trial will test a new accelerated 5-day rTMS protocol for treating symptoms of depression and OCD. The goal is to improve symptoms and identify biomarkers for depression and OCD.

Who is the study for?
This trial is for adults with major depression or OCD who haven't improved after trying at least one medication. They must be stable on their current antidepressants, if any, and able to consent. People with psychotic symptoms, recent substance abuse, significant neurological disorders, imminent suicide risk, or other primary psychiatric diagnoses besides OCD or mild anxiety are excluded.Check my eligibility
What is being tested?
The study tests an accelerated 5-day rTMS treatment using the MagVenture MagPro System aimed at rapidly improving depression and OCD symptoms. Participants will undergo fMRI scans to find biomarkers predicting TMS benefits. They'll receive intense daily rTMS sessions targeting specific brain areas over a week, possibly followed by another course if partially responsive.See study design
What are the potential side effects?
rTMS may cause discomfort at the stimulation site, headache, lightheadedness or seizures in rare cases. The intensity of side effects can vary from person to person.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with major depression or OCD.
Select...
My current depression treatment hasn't worked despite proper dosage and time.
Select...
I am not on antidepressants or have been on a stable dose for 4+ weeks.
Select...
I am able to understand and agree to the study's procedures and risks.
Select...
I have been diagnosed with major depression or OCD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores for participants with treatment resistant depression
Percent Change in Yale-Brown Obsessive Compulsive Scale (YBOCS) scores for participants with OCD
Secondary outcome measures
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with OCD
Change in resting-state fMRI connectivity between the frontostriatal network and limbic network in participants with treatment resistant depression
Percent Change in 17-item Hamilton Depression Rating Scale (HAM-D) scores for participants with treatment resistant depression
+7 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Group I: OCD - DMPFC target to (for non-responders) LPFC targetExperimental Treatment1 Intervention
Participants with OCD will receive a 5-day course of rTMS delivered to the DMPFC.Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
Group II: Depression - DMPFC target to (for non-responders) LPFC targetExperimental Treatment1 Intervention
Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the DMPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (LPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
Group III: OCD - LPFC target to (for non-responders) DMPFC targetActive Control1 Intervention
Participants with OCD will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.
Group IV: Depression - LPFC target to (for non-responders) DMPFC targetActive Control1 Intervention
Participants with treatment resistant depression will receive a 5-day course of rTMS delivered to the LPFC. Participants may have the option to be crossed over to receive rTMS targeting the opposite brain area (DMPFC), enabling us to test whether participants who do not respond well to one target might respond to stimulation of another target. The option to offer a second course of treatment will be based on clinical judgement and re-evaluation of the participant.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,047 Previous Clinical Trials
1,328,106 Total Patients Enrolled
66 Trials studying Depression
16,098 Patients Enrolled for Depression
The New Venture Fund / Foundation for OCD ResearchUNKNOWN
The Wellcome Leap FundUNKNOWN

Media Library

Accelerated TMS (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04982757 — N/A
Depression Research Study Groups: OCD - LPFC target to (for non-responders) DMPFC target, Depression - LPFC target to (for non-responders) DMPFC target, OCD - DMPFC target to (for non-responders) LPFC target, Depression - DMPFC target to (for non-responders) LPFC target
Depression Clinical Trial 2023: Accelerated TMS Highlights & Side Effects. Trial Name: NCT04982757 — N/A
Accelerated TMS (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04982757 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size of this research study?

"Yes, according to clinicaltrials.gov this medical research is presently recruiting patients. Initially posted on August 18th 2021 and last edited June 27th 2022, the study seeks 300 participants at a single site."

Answered by AI

What are the eligibility requirements for participation in this research project?

"This clinical trial, which is open to adults aged 18-70 with depression and OCD, seeks 300 participants. The necessary criteria for enrolment include a failure of current treatment despite adequate dosing; DSM-V diagnosis of major depressions disorder or obsessive compulsive disorder; Hamilton Depression Rating Scale score greater than 18 OR Yale-Brown Obsessive Compulsive Scale score higher than 16; stable dose of antidepressants for at least 4 weeks with plans to remain on this dosage during the study; and capacity to give informed consent."

Answered by AI

Does this trial accept senior citizens as participants?

"This medical trial is open to patients who are 18 years or older, but not yet 70."

Answered by AI

Are there still opportunities available to participate in this medical experiment?

"Per the clinicaltrials.gov registry, this research is actively recruiting patient populations; the study was first advertised on August 18th 2021 and underwent its latest update June 27th 2022."

Answered by AI

What are the key objectives of this experimental procedure?

"Over the Baseline to Treatment End: Day 5, 10, 15 or 20 (depending on number of courses administered) period for this trial, investigators will assess the Percent Change in Yale-Brown Obsessive Compulsive Scale scores. Additionally, they shall measure the change in Beck Anxiety Inventory results (ranging from 0 - 63), General Anxiety Disorder rankings (from 0 - 21), and resting-state fMRI connectivity between frontostriatal network and limbic network (between 0 - 1)."

Answered by AI

Who else is applying?

What state do they live in?
Quebec
New Jersey
Other
New York
How old are they?
18 - 65
What site did they apply to?
Weill Cornell Medicine
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+
0
1

What questions have other patients asked about this trial?

How invasive is the trial?
PatientReceived no prior treatments

Why did patients apply to this trial?

3 or more medications. I’ve tried other drugs/methods that did not work.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Email
~139 spots leftby May 2026